Page 1 |
Save page Remove page | Previous | 1 of 71 | Next |
|
small (250x250 max)
medium (500x500 max)
large ( > 500x500)
Full Resolution
All (PDF)
|
This page
All
Subset |
MPTP MODEL OF PARKINSON'S DISEASE: MECHANISMS OF NEURODEGENERATION AND POTENTIAL NEUROPROTECTIVE COMPOUNDS
by
Ludwig Hamo
A Dissertation Presented to the
FACULTY OF THE GRADUATE SCHOOL
UNIVERSTIY OF SOUTHERN CALIFORNIA
In Partial Fulfillment of the
Requirements for the Degree
DOCTOR OF PHILOSOPHY
(NEUROSCIENCE)
December 2007
Copyright 2007 Ludwig Hamo
Object Description
| Title | MPTP model of Parkinson's disease: mechanisms of neurodegeneration and potential neuroprotective compounds |
| Author | Hamo, Ludwig |
| Author email | hamo@usc.edu |
| Degree | Doctor of Philosophy |
| Document type | Dissertation |
| Degree program | Neuroscience |
| School | College of Letters, Arts and Sciences |
| Date defended/completed | 2007-07-24 |
| Date submitted | 2007 |
| Restricted until | Unrestricted |
| Date published | 2007-10-01 |
| Advisor (committee chair) | Baudry, Michel |
| Advisor (committee member) |
Swanson, Larry Petruska, John |
| Abstract | Parkinson's disease is a neurodegenerative disease second only to Alzheimer's disease in the number of people afflicted each year. The causes leading to this multicentric disease are unknown. The state of therapy for this disease is such that all available drugs treat symptoms and delay the crippling symptoms of motor dysfunction that ultimately lower the life expectancy of patients. In the present two studies, we have pursued two different approaches to treating potential mechanisms leading to the selective neurodegeneration of dopaminergic neurons, thus retarding or preventing the disease. First, we examine the possibility of increasing endogenous brain-derived neurotrophic factor (BDNF) via ampakines, a class of cognitive enhancing drugs that have already been tested on humans and have shown to increase BDNF in animals. Second, we test a class of drugs with catalytic antioxidant activity as well the ability to inhibit mitochondrial permeability transition pores. In both instances the MPTP model of PD is employed in rodents, which has been identified as the toxin-induced model most closely resembling symptoms observed in Parkinson's disease. |
| Keyword | Parkinson's disease; neurodegeneration; neuroprotective; MPTP |
| Language | English |
| Part of collection | University of Southern California dissertations and theses |
| Publisher (of the original version) | University of Southern California |
| Place of publication (of the original version) | Los Angeles, California |
| Publisher (of the digital version) | University of Southern California. Libraries |
| Type | texts |
| Legacy record ID | usctheses-m834 |
| Rights | Hamo, Ludwig |
| Repository name | Libraries, University of Southern California |
| Repository address | Los Angeles, California |
| Repository email | http://www.usc.edu/isd/libraries/services/ask_a_librarian/email/ |
| Filename | etd-Hamo-20071001 |
| Archival file | uscthesesreloadpub_Volume14/etd-Hamo-20071001.pdf |
Description
| Title | Page 1 |
| Full text | MPTP MODEL OF PARKINSON'S DISEASE: MECHANISMS OF NEURODEGENERATION AND POTENTIAL NEUROPROTECTIVE COMPOUNDS by Ludwig Hamo A Dissertation Presented to the FACULTY OF THE GRADUATE SCHOOL UNIVERSTIY OF SOUTHERN CALIFORNIA In Partial Fulfillment of the Requirements for the Degree DOCTOR OF PHILOSOPHY (NEUROSCIENCE) December 2007 Copyright 2007 Ludwig Hamo |
Comments
Post a Comment for Page 1
